Ohio is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
NCT02143830
Recruiting
The purpose of this study is to determine whether the use of lower doses of busulfan and the elimination of cyclosporine will further reduce transplant-related side effects for patients with Fanconi Anemia (FA). Patients will undergo a transplant utilizing mis-matched related or matched unrelated donors following a preparative regimen of busulfan, fludarabine, anti-thymocyte globulin and cyclophosphamide.
Gender:
ALL
Ages:
3 months and above
Trial Updated:
12/09/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Fanconi Anemia, Severe Marrow Failure, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML)
Register for Updates
Donor-Derived Viral Specific T-cells (VSTs)
NCT02048332
Recruiting
In this research study, the investigators want to learn more about the use of donor-derived viral specific T-cells (VSTs) to treat viral infections that occur after allogeneic stem cell transplant. A viral specific T cell is a T lymphocyte (a type of white blood cell) that kills cells that are infected (particularly with viruses). Allogeneic means the stem cells come from another person. These VSTs are cells specially designed to fight the virus infections that can happen after a bone marrow tra... Read More
Gender:
ALL
Ages:
4 weeks and above
Trial Updated:
12/09/2024
Locations: Akron Children's Hospital, Akron, Ohio
Conditions: Allogeneic Stem Cell Transplant, Viral Infection, Viral Reactivation
Register for Updates
Post-Stroke Sensory Reweighting on Walking and Balance Outcomes
NCT06727097
Recruiting
The primary objective of this proof-of-concept study is to longitudinally track the development of post-stroke sensory reweighting (PSR), identify associated structural neuroanatomical correlates, and investigate their relationship to walking and fall outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: University of Cincinnati College of Medicine, Cincinnati, Ohio
Conditions: Ischemic Stroke
Register for Updates
Comprehensive Outcomes for After Cancer Health
NCT05349227
Recruiting
This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer diagnoses will be enrolled across up to 8 clinical sites to participate in a randomized wait-list control study. Those in the intervention group will receive 6 months of digital coaching up front followed by 6 months of ongoing monitoring via patient reported and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Survivorship, Endometrial Cancer, Head and Neck Cancers, Prostate Cancers, Geriatric Oncology, Metastatic Breast Cancer, Metastatic Cancer
Register for Updates
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRĪ±)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT04300556
Recruiting
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer \[OC\], endometrial cancer \[EC\], non-small cell lung carcinoma \[NSCLC\], triple-negative breast cancer \[TNBC\]), and (2) in dose-confirmation part: to evaluate preliminary efficacy measured by objective response rate (ORR) of farletuzu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Solid Tumor
Register for Updates
Brain Oxygen Optimization in Severe TBI, Phase 3
NCT03754114
Recruiting
BOOST3 is a randomized clinical trial to determine the comparative effectiveness of two strategies for monitoring and treating patients with traumatic brain injury (TBI) in the intensive care unit (ICU). The study will determine the safety and efficacy of a strategy guided by treatment goals based on both intracranial pressure (ICP) and brain tissue oxygen (PbtO2) as compared to a strategy guided by treatment goals based on ICP monitoring alone. Both of these alternative strategies are used in s... Read More
Gender:
ALL
Ages:
14 years and above
Trial Updated:
12/06/2024
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Brain Injuries, Traumatic
Register for Updates
Comparing Stainless Steel Crowns with Prefabricated Resin Crowns in Primary Molar Teeth
NCT06713330
Recruiting
The main reason for this research study is to learn more about a new flexible white dental crown (BioFLX) by comparing it to an existing flexible metal crown (Stainless Steel Crown). It is of interest to see if this new white crown is clinically equivalent to the existing silver crown that is mainly used in pediatric dentistry. A potential participant for this study would have cavities that require a crown, a type of filling that covers the entire tooth, and recommended dental work be done under... Read More
Gender:
ALL
Ages:
Between 2 years and 5 years
Trial Updated:
12/05/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Dental Caries
Register for Updates
The Oxford Risk Factors And Non-Invasive Imaging Study
NCT05169333
Recruiting
ORFAN is a prospective, multi-centre, multi-ethnic cohort observational study collecting CT scans, biological material and outcomes data, to develop and validate novel biomarkers of cardiometabolic and other disease risk.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
12/05/2024
Locations: Cleveland Clinic Heart and Vascular Institute, Cleveland, Ohio
Conditions: Cardiovascular Diseases, Cardiovascular Risk Factors
Register for Updates
Stroke Thrombectomy and Aneurysm Registry
NCT04994756
Recruiting
This international multi-center registry is used to collect existing information and outcomes for patients undergoing an operation for treatment of injuries to the brain including the blockage of blood flow to an area of the brain, an abnormal ballooning of an artery, abnormal tangling of blood vessels, abnormal formation of blood vessels, tearing of vein, and bleeding in the brain. This information is used to help predict outcomes that undergo an operation for treatment of the above-listed brai... Read More
Gender:
ALL
Ages:
Between 1 year and 120 years
Trial Updated:
12/05/2024
Locations: Mercy Health, Toledo, Ohio
Conditions: Stroke, Thromboses, Intracranial, Aneurysm, Brain
Register for Updates
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
NCT04981795
Recruiting
The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: Mercy Medical Center, Canton, Ohio
Conditions: Diffuse Large B-cell Lymphoma
Register for Updates
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
NCT05476770
Recruiting
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed/refractory hematologic malignancies. The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is pre... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
12/04/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
Register for Updates
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
NCT05361174
Recruiting
This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/04/2024
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Register for Updates